How Many EP Patents Exist? EP 226 & 378 Explained
In the intricate world of , questions like how many EP are there often arise when analyzing legal documents related to patent disputes. Here, EP refers to , a critical form of protection granted under the (EPC). These patents can play pivotal roles in litigation involving , , and essentiality for technical standards. Based on specific legal materials, evidence points to at least two key EP patents: EP 226 and EP 378. This post breaks down their mentions, contexts, and implications, while weaving in broader legal insights for a comprehensive view.
Whether you're a patent attorney, inventor, or business navigating IP rights, understanding these references can shed light on patent enforceability. Note: This is general information, not specific legal advice—consult a qualified professional for your situation.
Understanding EP Patents in Legal Contexts
(EPs) provide exclusive rights across multiple European countries upon validation. They are frequently scrutinized in opposition proceedings, , and (SEP) declarations. The query how many EP are there typically seeks a count within a defined scope, such as case documents. In the reviewed materials, only two EPs are explicitly identified: EP 226 and EP 378. No others are mentioned, limiting the count to these. 2012 0 Supreme(Del) 2203
EP 226: The Powerhouse
EP 226 emerges as a cornerstone in patentability discussions, particularly as . It is referenced extensively in relation to Example 51, described as a preferred compound in anti-cancer applications. A key quote states: The closest for this case in comparison with the Claim 1 is Example 51 of EP‘226. 2012 0 Supreme(Del) 2203
- Key Discussions:
- Inventive step analysis: Courts or examiners compare claims against EP 226's disclosures to assess novelty.
- Role as preferred compound: Highlights its technical significance, potentially impacting .
- Legal Relevance: Confirms EP 226's existence and active citation in .
This patent's repeated mentions underscore its influence in pharmaceutical and chemical patent landscapes. Typically, such can derail later patents if similarities are too close.
EP 378: Linked to Regulatory and
EP 378, corresponding to Canadian patent CA 176 and noted as EP 1294378, is tied to pharmaceutical products like REVOLADE. It has been extended via (SPCs), which prolong exclusivity post-regulatory approval. The documents note: IN 176 corresponded to European Patent EP 1294378 (''''EP 378'''', in short).
- Key Aspects:
- Essentiality for standards: Evaluated for DVD standards or similar technical contexts.
- : Demonstrates ongoing commercial viability and legal protection.
- Cross-Jurisdictional Ties: Mirrors protections in Canada, emphasizing global strategy.
EP 378's status suggests it remains enforceable, with discussions on scope and regulatory interplay.
Detailed Analysis: Scope and Limitations
The legal texts focus on patent validity, inventive step, and claim scope, confirming these two EPs' existence without referencing others. Here's a breakdown:
| Patent | Main Context | Key Quote/Document ||--------|--------------|-------------------|| EP 226 | , Example 51 | Example 51 of EP‘226 2012 0 Supreme(Del) 2203 || EP 378 | SPCs, REVOLADE approvals | EP 1294378 (EP 378)
|
- No Additional EPs: Searches within the documents yield no further specifics, indicating a case-specific count of two.
- Broader Implications: Inventive step requires demonstrating non-obviousness over art like EP 226. Essentiality, as with EP 378, affects in SEPs.
Limitations include the narrow document scope— a full (EPO) database search might reveal more, but here, it's two. 2012 0 Supreme(Del) 2203
Related Legal Contexts: Parallels in Other Areas
While EP denotes here, similar abbreviations appear elsewhere, offering useful contrasts. In Indian labor law, Employees' Provident Fund (EPF) cases frequently involve inquiries into contributions and liabilities, mirroring patent validity probes.
For instance, courts emphasize under the , Section 7A, basing assessments on , not averages. One ruling held: The assessment of PF contributions must be based on drawn by employees. 2024 0 Supreme(Ker) 778 The has standing to challenge tribunal orders, ensuring proper processes. 2024 0 Supreme(Ker) 778
Another case quashed malicious complaints against EPF/ESI officers, protecting good-faith actions: The court found complaint malicious, lacking merit, and filed to evade . 2024 0 Supreme(P&H) 1097 This parallels patent oppositions where baseless challenges are dismissed.
In insolvency contexts, preserving employment (linked to EPF) is prioritized: preserve its values and employment of many people directly and indirectly. 2026 Supreme(Online)(Tel) 3963
These EPF examples highlight procedural rigor akin to EPO examinations—thorough evidence review prevents presumptive decisions. Though unrelated directly, they illustrate how EP-related queries demand precise contextual analysis.
Strategic Recommendations for IP Stakeholders
- Patent Search Best Practices: Always cross-reference EPO registers for full EP counts beyond case files.
- : Leverage EP 226 as in pharma disputes.
- SPC Planning: Model after EP 378 for drug extensions.
- Global Filings: Align with counterparts like CA 176.
For comprehensive audits, consult databases; within these docs, stick to two EPs.
Key Takeaways
- Answer to 'How Many EP Are There?': Two—EP 226 and EP 378—in the provided legal context. 2012 0 Supreme(Del) 2203
- EP 226 dominates talks; EP 378 shines in regulatory extensions.
- Broader lessons from EPF cases stress evidence-based inquiries.
- Patents evolve through challenges—stay vigilant on and essentiality.
This analysis equips you with foundational insights into these EPs. For tailored advice, engage IP counsel. Explore more on patent law to safeguard innovations effectively.
#EuropeanPatents, #PatentLaw, #IPInsights
